BioLineRx (BLRX) Earnings Analysis

BioLineRx (BLRX) next reports earnings on 2026-08-13, consensus EPS -0.15 USD. Last quarter (2026-05-27) it beat with EPS -0.36 USD vs -1.04 USD est (+65.4%). It has beaten estimates in 5/7 recent quarters (71%). Trailing P/E -1.36.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does BLRX next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.15 USD
Revenue estimate0.00B

BLRX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-27-0.36 USD-1.04 USD+65.4%Beat
2026-03-23-0.27 USD-0.385 USD+29.9%Beat
2025-11-24-0.22 USD-0.41 USD+46.3%Beat
2025-08-14-1 USD-0.35 USD-185.7%Miss
2025-05-271.39 USD-0.84 USD+265.5%Beat
2024-11-25-2.8 USD-0.05 USD-5500%Miss
2024-08-150.4 USD-0.14 USD+385.7%Beat

Beat rate: 5/7 (71%) over reported quarters with consensus data.

BLRX valuation and analyst view

Trailing P/E-1.36
Trailing EPS-0.0502 USD
Price / book0.78
Dividend yield0.00%
Market cap0.01B
Analyst consensusBuy (7 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is BioLineRx (BLRX)'s next earnings date?

BioLineRx is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.15 USD and revenue estimate of 0.00B.

Did BLRX beat earnings last quarter?

In its 2026-05-27 report, BLRX posted EPS of -0.36 USD versus a -1.04 USD estimate — a beat of 65.4%.

What is BLRX's earnings track record?

Over the last 7 reported quarters with consensus data, BLRX beat estimates 5 times (71%).

What is BLRX's current P/E ratio and EPS?

BLRX trades at a trailing P/E of -1.36 on trailing EPS of -0.0502 USD.

What do analysts rate BLRX?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell).